Top

Breast Cancer Research and Treatment

Published in:

01-12-2019 | Breast Cancer | Preclinical study

CpG methylation signature predicts prognosis in breast cancer

Authors: Tonghua Du, Bin Liu, Zhenyu Wang, Xiaoyu Wan, Yuanyu Wu

Published in: Breast Cancer Research and Treatment | Issue 3/2019

Abstract

Purpose

DNA methylation can be used as prognostic biomarkers in various types of cancers. We aimed to identify a CpG methylation pattern for breast cancer.

Methods

In this study, using the microarray data from the cancer genome atlas (TCGA) and gene expression omnibus (GEO), we profiled DNA methylation between 97 healthy control samples and 786 breast cancer samples in a training cohort (from TCGA, n = 883) to build a gene classifier using a penalized regression model. We validated the prognostic accuracy of this gene classifier in an internal validation cohort (from GEO, n = 72).

Results

A total of 1777 differentially methylated CpGs corresponding to 1777 different methylated genes (DMGs) between breast cancer and control were chosen for this study. Subsequently, 16 CpGs were generated to classify patients into high-risk and low-risk groups in the training cohort. Patients with high-risk scores in the training cohort had shorter overall survival (hazard ratio [HR], 4.674; 95% CI 2.918 to 7.487; P = 1.678e–12) than patients with low-risk scores. The prognostic accuracy was also validated in the validation cohorts. Furthermore, among patients with low-risk scores in the combined training and validation cohorts, the patients with the age > 60 years compared with the patients with the age < 60 years were associated with improved overall survival (HR 2.088, 95% CI 1.348 to 3.235; p = 7.575e–04) in patients with a high-risk score but not in patients with low-risk score (HR 1.246, 95% CI 0.515 to 3.011; p = 0.625). The patients treated with radiotherapy compared with the patients without radiotherapy were associated with improved overall survival (HR 0.418, 95% CI 0.249 to 0.703; p = 6.991e-04) in patients with a high-risk score but not in patients with low-risk score (HR 2.092, 95% CI 0.574 to 7.629; p = 0.253). For the patients with recurrence and the patients without recurrence both groups were all associated with improved overall survival (HR 7.475, 95% CI 4.333 to 12.901; p = 6.991e–04) in patients with a high-risk score and in patients with low-risk score (HR 14.33, 95% CI 4.265 to 48.17; p = 4.883e–13).

Conclusion

The 16 CpG-based signature is useful as a biomarker in predicting prognosis for patients with breast cancer.

Available only for authorised users

Johnson RH, Chien FL, Bleyer A (2013) Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009. JAMA 309(8):800–805. https://doi.org/10.1001/jama.2013.7761656255 CrossRefPubMed

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–386. https://doi.org/10.1002/ijc.29210 CrossRef

Tang Q, Holland-Letz T, Slynko A, Cuk K, Marme F, Schott S, Heil J, Qu B, Golatta M, Bewerunge-Hudler M, Sutter C, Surowy H, Wappenschmidt B, Schmutzler R, Hoth M, Bugert P, Bartram CR, Sohn C, Schneeweiss A, Yang R, Burwinkel B (2016) DNA methylation array analysis identifies breast cancer associated RPTOR, MGRN1 and RAPSN hypomethylation in peripheral blood DNA. Oncotarget 7(39):64191–64202. https://doi.org/10.18632/oncotarget.1164011640 CrossRefPubMedPubMedCentral

Cady B (2007) Local therapy and survival in breast cancer. N Engl J Med 357(10):1051–1052 author reply 1052 CrossRef

Hudis CA (2007) Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med 357(1):39–51CrossRef

Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128(4):683–692CrossRef

Bibikova M, Barnes B, Tsan C, Ho V, Klotzle B, Le JM, Delano D, Zhang L, Schroth GP, Gunderson KL, Fan JB, Shen R (2011) High density DNA methylation array with single CpG site resolution. Genomics 98(4):288–295CrossRef

Gentleman R, Carey VJ, Huber W, Irizarry RA, Dudoit S (2005) Bioinformatics and computational biology solutions using R and Bioconductor. Springer, New YorkCrossRef

Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B (Methodological) 57(1):289–300

10.

Langfelder P, Horvath S (2008) WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9:559CrossRef

11.

Wang P, Wang Y, Hang B, Zou X, Mao JH (2016) A novel gene expression-based prognostic scoring system to predict survival in gastric cancer. Oncotarget 7(34):55343–55351PubMedPubMedCentral

12.

Goeman JJ (2010) L1 penalized estimation in the Cox proportional hazards model. Biom J 52(1):70–84. https://doi.org/10.1002/bimj.200900028 CrossRefPubMed

13.

Tibshirani R (1997) The lasso method for variable selection in the Cox model. Stat Med 16(4):385–395CrossRef

14.

Shan M, Zhang L, Liu Y, Gao C, Kang W, Yang W, He Y, Zhang G (2019) DNA methylation profiles and their diagnostic utility in BC. Dis Mark 2019:6328503. https://doi.org/10.1155/2019/6328503 CrossRef

15.

Lesicka M, Jablonska E, Wieczorek E, Seroczynska B, Kalinowski L, Skokowski J, Reszka E (2019) A different methylation profile of circadian genes promoter in breast cancer patients according to clinicopathological features. Chronobiol Int. https://doi.org/10.1080/07420528.2019.1617732 CrossRefPubMed

16.

Yang Y, Wu L, Shu XO, Cai Q, Shu X, Li B, Guo X, Ye F, Michailidou K, Bolla MK, Wang Q, Dennis J, Andrulis IL, Brenner H, Chenevix-Trench G, Campa D, Castelao JE, Gago-Dominguez M, Dork T, Hollestelle A, Lophatananon A, Muir K, Neuhausen SL, Olsson H, Sandler DP, Simard J, Kraft P, Pharoah PDP, Easton DF, Zheng W, Long J (2019) Genetically predicted levels of DNA methylation biomarkers and breast cancer risk: data from 228,951 women of European descent. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djz109 CrossRefPubMedPubMedCentral

17.

He LH, Ma Q, Shi YH, Ge J, Zhao HM, Li SF, Tong ZS (2013) CHL1 is involved in human breast tumorigenesis and progression. Biochem Biophys Res Commun 438(2):433–438CrossRef

18.

Martin-Sanchez E, Mendaza S, Ulazia-Garmendia A, Monreal-Santesteban I, Blanco-Luquin I, Cordoba A, Vicente-Garcia F, Perez-Janices N, Escors D, Megias D, Lopez-Serra P, Esteller M, Illarramendi JJ, Guerrero-Setas D (2017) CHL1 hypermethylation as a potential biomarker of poor prognosis in breast cancer. Oncotarget 8(9):15789–15801CrossRef

19.

Cao WH, Liu XP, Meng SL, Gao YW, Wang Y, Ma ZL, Wang XG, Wang HB (2016) USP4 promotes invasion of breast cancer cells via Relaxin/TGF-beta1/Smad2/MMP-9 signal. Eur Rev Med Pharmacol Sci 20(6):1115–1122PubMed

20.

Li Y, Jiang D, Zhang Q, Liu X, Cai Z (2016) Ubiquitin-specific protease 4 inhibits breast cancer cell growth through the upregulation of PDCD4. Int J Mol Med 38(3):803–811. https://doi.org/10.3892/ijmm.2016.2685 CrossRefPubMedPubMedCentral

21.

Turner AW, Nikpay M, Silva A, Lau P, Martinuk A, Linseman TA, Soubeyrand S, McPherson R (2015) Functional interaction between COL4A1/COL4A2 and SMAD3 risk loci for coronary artery disease. Atherosclerosis 242(2):543–552CrossRef

22.

JingSong H, Hong G, Yang J, Duo Z, Li F, WeiCai C, XueYing L, YouSheng M, YiWen O, Yue P, Zou C (2017) siRNA-mediated suppression of collagen type IV alpha 2 (COL4A2) mRNA inhibits triple-negative breast cancer cell proliferation and migration. Oncotarget 8(2):2585–2593PubMed

23.

Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24(23):3726–3734CrossRef

24.

Suzuki MM, Bird A (2008) DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet 9(6):465–476CrossRef

25.

Teschendorff AE, Menon U, Gentry-Maharaj A, Ramus SJ, Gayther SA, Apostolidou S, Jones A, Lechner M, Beck S, Jacobs IJ, Widschwendter M (2009) An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS ONE 4(12):e8274. https://doi.org/10.1371/journal.pone.0008274 CrossRefPubMedPubMedCentral

Title: CpG methylation signature predicts prognosis in breast cancer
Authors: Tonghua Du
Bin Liu
Zhenyu Wang
Xiaoyu Wan
Yuanyu Wu
Publication date: 01-12-2019
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Radiotherapy
Published in: Breast Cancer Research and Treatment / Issue 3/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-019-05417-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2019

Prognostic value of receptor status conversion following neoadjuvant chemotherapy in breast cancer patients: a systematic review and meta-analysis

Chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer survivors: a comparison of patient-reported outcomes and quantitative sensory testing

Effectiveness of radiotherapy after breast-conserving surgery in older patients with T1-2N0 breast cancer

Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?

Cost-utility, cost-effectiveness, and budget impact of Internet-based cognitive behavioral therapy for breast cancer survivors with treatment-induced menopausal symptoms

The microbiome and breast cancer: a review

Keynote webinar | Spotlight on antibody–drug conjugates in cancer